BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31285596)

  • 1. Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.
    Böttcher J; Dilworth D; Reiser U; Neumüller RA; Schleicher M; Petronczki M; Zeeb M; Mischerikow N; Allali-Hassani A; Szewczyk MM; Li F; Kennedy S; Vedadi M; Barsyte-Lovejoy D; Brown PJ; Huber KVM; Rogers CM; Wells CI; Fedorov O; Rumpel K; Zoephel A; Mayer M; Wunberg T; Böse D; Zahn S; Arnhof H; Berger H; Reiser C; Hörmann A; Krammer T; Corcokovic M; Sharps B; Winkler S; Häring D; Cockcroft XL; Fuchs JE; Müllauer B; Weiss-Puxbaum A; Gerstberger T; Boehmelt G; Vakoc CR; Arrowsmith CH; Pearson M; McConnell DB
    Nat Chem Biol; 2019 Aug; 15(8):822-829. PubMed ID: 31285596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth.
    Sun Y; Xie J; Cai S; Wang Q; Feng Z; Li Y; Lu JJ; Chen W; Ye Z
    Cell Death Dis; 2021 Oct; 12(10):913. PubMed ID: 34615858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone and DNA binding ability studies of the NSD subfamily of PWWP domains.
    Zhang M; Yang Y; Zhou M; Dong A; Yan X; Loppnau P; Min J; Liu Y
    Biochem Biophys Res Commun; 2021 Sep; 569():199-206. PubMed ID: 34271259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells.
    Xu C; Meng F; Park KS; Storey AJ; Gong W; Tsai YH; Gibson E; Byrum SD; Li D; Edmondson RD; Mackintosh SG; Vedadi M; Cai L; Tackett AJ; Kaniskan HÜ; Jin J; Wang GG
    Cell Chem Biol; 2022 Mar; 29(3):386-397.e9. PubMed ID: 34469831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated NSD3 histone methylation activity drives squamous cell lung cancer.
    Yuan G; Flores NM; Hausmann S; Lofgren SM; Kharchenko V; Angulo-Ibanez M; Sengupta D; Lu X; Czaban I; Azhibek D; Vicent S; Fischle W; Jaremko M; Fang B; Wistuba II; Chua KF; Roth JA; Minna JD; Shao NY; Jaremko Ł; Mazur PK; Gozani O
    Nature; 2021 Feb; 590(7846):504-508. PubMed ID: 33536620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming properties of 8p11-12 amplified genes in human breast cancer.
    Yang ZQ; Liu G; Bollig-Fischer A; Giroux CN; Ethier SP
    Cancer Res; 2010 Nov; 70(21):8487-97. PubMed ID: 20940404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors.
    Li N; Yang H; Liu K; Zhou L; Huang Y; Cao D; Li Y; Sun Y; Yu A; Du Z; Yu F; Zhang Y; Wang B; Geng M; Li J; Xiong B; Xu S; Huang X; Liu T
    J Med Chem; 2022 Jul; 65(13):9459-9477. PubMed ID: 35704853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.
    Shen C; Ipsaro JJ; Shi J; Milazzo JP; Wang E; Roe JS; Suzuki Y; Pappin DJ; Joshua-Tor L; Vakoc CR
    Mol Cell; 2015 Dec; 60(6):847-59. PubMed ID: 26626481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction.
    Xiong J; Pecchi VG; Qui M; Ivanov AA; Mo X; Niu Q; Chen X; Fu H; Du Y
    Assay Drug Dev Technol; 2018; 16(2):96-106. PubMed ID: 29634317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3.
    Turner-Ivey B; Smith EL; Rutkovsky AC; Spruill LS; Mills JN; Ethier SP
    Breast Cancer Res Treat; 2017 Jul; 164(2):349-358. PubMed ID: 28484924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression.
    Jeong GY; Park MK; Choi HJ; An HW; Park YU; Choi HJ; Park J; Kim HY; Son T; Lee H; Min KW; Oh YH; Lee JY; Kong G
    Cancer Res; 2021 Jan; 81(1):77-90. PubMed ID: 32967925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis.
    Liu Z; Piao L; Zhuang M; Qiu X; Xu X; Zhang D; Liu M; Ren D
    Oncol Rep; 2017 Nov; 38(5):2796-2802. PubMed ID: 28901481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.
    Dilworth D; Hanley RP; Ferreira de Freitas R; Allali-Hassani A; Zhou M; Mehta N; Marunde MR; Ackloo S; Carvalho Machado RA; Khalili Yazdi A; Owens DDG; Vu V; Nie DY; Alqazzaz M; Marcon E; Li F; Chau I; Bolotokova A; Qin S; Lei M; Liu Y; Szewczyk MM; Dong A; Kazemzadeh S; Abramyan T; Popova IK; Hall NW; Meiners MJ; Cheek MA; Gibson E; Kireev D; Greenblatt JF; Keogh MC; Min J; Brown PJ; Vedadi M; Arrowsmith CH; Barsyte-Lovejoy D; James LI; Schapira M
    Nat Chem Biol; 2022 Jan; 18(1):56-63. PubMed ID: 34782742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
    French CA; Rahman S; Walsh EM; Kühnle S; Grayson AR; Lemieux ME; Grunfeld N; Rubin BP; Antonescu CR; Zhang S; Venkatramani R; Dal Cin P; Howley PM
    Cancer Discov; 2014 Aug; 4(8):928-41. PubMed ID: 24875858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.
    Sun Y; Zhang Y; Chen X; Yu A; Du W; Huang Y; Wu F; Yu L; Li J; Wen C; Yang H; Shi Q; Geng M; Huang X; Xu S
    Eur J Med Chem; 2022 Sep; 239():114528. PubMed ID: 35717870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
    Ferreira de Freitas R; Liu Y; Szewczyk MM; Mehta N; Li F; McLeod D; Zepeda-Velázquez C; Dilworth D; Hanley RP; Gibson E; Brown PJ; Al-Awar R; James LI; Arrowsmith CH; Barsyte-Lovejoy D; Min J; Vedadi M; Schapira M; Allali-Hassani A
    J Med Chem; 2021 Feb; 64(3):1584-1592. PubMed ID: 33522809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NSD3 in Cancer: Unraveling Methyltransferase-Dependent and Isoform-Specific Functions.
    Nuñez Y; Vera S; Baeza V; Gonzalez-Pecchi V
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of histone methyltransferase NSD3 on ISO-induced cardiac hypertrophy.
    Chen K; Jian D; Zhao L; Zang X; Song W; Ma J; Jia Z; Wang X; Gao C
    FEBS Lett; 2019 Sep; 593(18):2556-2565. PubMed ID: 31254363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NSD family of protein methyltransferases in human cancer.
    Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
    Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The methyltransferase NSD3 promotes antiviral innate immunity via direct lysine methylation of IRF3.
    Wang C; Wang Q; Xu X; Xie B; Zhao Y; Li N; Cao X
    J Exp Med; 2017 Dec; 214(12):3597-3610. PubMed ID: 29101251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.